LeonaBio (LONA) Share-based Compensation (2019 - 2026)
LeonaBio (LONA) posted quarterly Share-based Compensation of $662000.0 for Q1 2026, down 59.56% year-over-year from $1.6 million in Q1 2025, and down 54.6% quarter-over-quarter from $1.5 million in Q4 2025.
LeonaBio (LONA) Share-based Compensation (2019 - 2026) Analysis & Trends
LeonaBio (LONA) has reported Share-based Compensation for 8 consecutive years, with $662000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Share-based Compensation fell 59.56% year-over-year to $662000.0; the TTM figure through Mar 2026 stood at $5.2 million (down 48.37% YoY), while the FY2025 annual figure was $6.1 million, down 44.77% from the prior year.
- Share-based Compensation eased to $662000.0 in Q1 2026 per LONA's latest filing, from $1.5 million in the prior quarter.
- Across five years, Share-based Compensation topped out at $6.2 million in Q2 2025 and bottomed at $662000.0 in Q1 2026.
- Historically, Share-based Compensation has averaged $2.6 million across 5 years, with a median of $2.5 million in 2023.
- Annual changes were most pronounced in 2022 — Share-based Compensation surged 180.39% — and 2026, when it slumped 59.56%.
- LeonaBio's Share-based Compensation stood at $2.4 million in 2022, then slipped by 5.59% to $2.2 million in 2023, then rose by 0.04% to $2.2 million in 2024, then slumped by 34.59% to $1.5 million in 2025, then sank by 54.6% to $662000.0 in 2026.
- Business Quant data shows LONA's Share-based Compensation at $662000.0 in Q1 2026, $1.5 million in Q4 2025, and $1.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.65 Bn | 130.80 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 85.93 Bn | 77.94 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 64.84 Bn | 59.66 Bn | 1.37 Bn | - |
| 4 | Moderna | 57.38 Bn | 52.25 Bn | 52.00 Mn | 120.00 Mn |
| 5 | BeOne Medicines | 41.94 Bn | 36.84 Bn | 1.53 Bn | 137.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.54 Bn | 28.23 Bn | 992.69 Mn | 86.63 Mn |
| 7 | BioNTech SE | 27.72 Bn | 9.33 Bn | 668.28 Mn | 28.05 Mn |
| 8 | Insmed | 27.49 Bn | 26.33 Bn | 358.27 Mn | 41.25 Mn |
| 9 | Royalty Pharma | 27.33 Bn | 26.49 Bn | - | - |
| 10 | LeonaBio | 182.22 Mn | 131.15 Mn | - | 37.10 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 662,000.00 |
| Mar 31, 2026 | 662,000.00 |
| Dec 31, 2025 | 1.46 Mn |
| Dec 31, 2025 | 1.46 Mn |
| Sep 30, 2025 | 1.41 Mn |
| Sep 30, 2025 | 1.41 Mn |
| Jun 30, 2025 | 6.20 Mn |
| Jun 30, 2025 | 6.20 Mn |
| Mar 31, 2025 | 1.64 Mn |
| Mar 31, 2025 | 1.64 Mn |
| Dec 31, 2024 | 2.23 Mn |
| Dec 31, 2024 | 2.23 Mn |
| Sep 30, 2024 | 2.94 Mn |
| Sep 30, 2024 | 2.94 Mn |
| Jun 30, 2024 | 3.21 Mn |
| Jun 30, 2024 | 3.21 Mn |
| Mar 31, 2024 | 2.68 Mn |
| Mar 31, 2024 | 2.68 Mn |
| Dec 31, 2023 | 2.23 Mn |
| Dec 31, 2023 | 2.23 Mn |